0000950170-24-069281.txt : 20240605 0000950170-24-069281.hdr.sgml : 20240605 20240605160506 ACCESSION NUMBER: 0000950170-24-069281 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: White William Richard CENTRAL INDEX KEY: 0001778739 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 241021964 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS, INC. STREET 2: 170 HARBOR WAY 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 674-9274 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0508 4 2024-06-03 0001816736 Disc Medicine, Inc. IRON 0001778739 White William Richard C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 true false false false true Common Stock 2024-06-03 4 M false 1756 2.65 A 1756 D Common Stock 2024-06-03 4 M false 201 9.86 A 1957 D Common Stock 2024-06-03 4 S false 107 35.1469 D 1850 D Common Stock 2024-06-03 4 S false 1755 36.1020 D 95 D Common Stock 2024-06-03 4 S false 95 36.7208 D 0 D Stock Option (Right to Buy) 2.65 2024-06-03 4 M false 1756 0.00 D 2030-11-26 Common Stock 1756 3512 D Stock Option (Right to Buy) 9.86 2024-06-03 4 M false 201 0.00 D 2031-09-13 Common Stock 201 3010 D The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 13, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.54 to $35.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.575 to $35.565, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.655 to $36.77, inclusive. The shares underlying this option vest in 16 equal quarterly installments following November 27, 2020, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option vest in 48 equal monthly installments following September 1, 2021, subject to the Reporting Person's continued service on each such vesting date. By: /s/ Rahul Khara, as Attorney-in-Fact 2024-06-05